CSIMarket



Amgen Inc   (AMGN)
Other Ticker:  
 
 

AMGN's Net Income Growth by Quarter and Year

Amgen Inc 's Net Income results by quarter and year




AMGN Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 1,899.00 1,615.00 1,703.00
III Quarter September - 1,884.00 2,021.00 1,968.00
II Quarter June - 464.00 1,803.00 2,179.00
I Quarter March 1,476.00 1,646.00 1,825.00 1,992.00
FY   1,476.00 5,893.00 7,264.00 7,842.00



AMGN Net Income first quarter 2022 Y/Y Growth Comment
Amgen Inc reported fall in Net Income in the first quarter 2022 by -10.33% to $ 1,476.00 millions, from the same quarter in 2021.
The decline in the first quarter 2022 Amgen Inc 's Net Income compares unfavorably to the Company's average Net Income growth of 4.18%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Net Income growth. While Amgen Inc ' s Net Income decrease of -10.33% ranks overall at the positon no. 1023 in the first quarter 2022.




AMGN Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 17.59 % -5.17 % -11.67 %
III Quarter September - -6.78 % 2.69 % 5.86 %
II Quarter June - -74.27 % -17.26 % -5.1 %
I Quarter March -10.33 % -9.81 % -8.38 % -13.8 %
FY   - -18.87 % -7.37 % -6.58 %

Financial Statements
Amgen Inc 's first quarter 2022 Net Income $ 1,476.00 millions AMGN's Income Statement
Amgen Inc 's first quarter 2021 Net Income $ 1,646.00 millions Quarterly AMGN's Income Statement
New: More AMGN's historic Net Income Growth >>


AMGN Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 0.8 % -20.09 % -13.47 %
III Quarter September - 306.03 % 12.09 % -9.68 %
II Quarter June - -71.81 % -1.21 % 9.39 %
I Quarter March -22.27 % 1.92 % 7.16 % 3.32 %
FY (Year on Year)   - -18.87 % -7.37 % -6.58 %




Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #68
Overall #1023

Net Income Y/Y Growth Statistics
High Average Low
281.2 % 4.18 % -75.8 %
(Dec 31 2018)   (Dec 31 2017)
Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #68
Overall #1023
Net Income Y/Y Growth Statistics
High Average Low
281.2 % 4.18 % -75.8 %
(Dec 31 2018)   (Dec 31 2017)

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Amgen Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
7771.43 % 120.15 % -98.6 %
(Sep. 30, 2006)  


AMGN's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2022 Amgen Inc realized fall in Net Income from the previous quarter by -22.27% to $ 1,476.00 millions, from $ 1,899.00 millions declared in the previous quarter.

Even cyclical influence which normally fuel I. Quarter 2022 results, have not rescue the I. Quarter for the Amgen Inc , Adrian Jönsson, a business advisor allocated in Goteborg said, he mentioned certan pessimism conserning Amgen Inc 's direction, he identified further difficulties ahead for Amgen Inc .

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Net Income quarter on quarter growth. While Amgen Inc 's Net Income growth quarter on quarter, overall rank is 900.


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #55
Overall #900
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #55
Overall #900
Net Income Q/Q Growth Statistics
High Average Low
7771.43 % 120.15 % -98.6 %
(Sep. 30, 2006)  


AMGN's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2022 Amgen Inc reported fall in Net Income from the forth quarter by -22.27% to $ 1,476.00 millions, from $ 1,899.00 millions achived in the previous quarter.

Even cyclical influence which commonly elevate I. Quarter 2022 performance, that clearly was not enough to salvage Biotechnology & Pharmaceuticals's company I. Quarter achievement, Adrian Jönsson, a business advisor allocated in Goteborg pointed out.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Net Income quarter on quarter growth. While Amgen Inc 's Net Income growth quarter on quarter, overall rank is 900.


Amgen Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Net Income 12 Months Ending $ 5,723.00 $ 5,893.00 $ 5,609.00 $ 5,746.00 $ 7,085.00
Y / Y Net Income Growth (TTM) -19.22 % -18.87 % -23.71 % -21.28 % -7.69 %
Year on Year Net Income Growth Overall Ranking # 1442 # 566 # 1033 # 1165 # 1310
Seqeuential Net Income Change (TTM) -2.88 % 5.06 % -2.38 % -18.9 % -2.46 %
Seq. Net Income Growth (TTM) Overall Ranking # 1023 # 375 # 1090 # 2112 # 1720




Cumulative Net Income growth Comment
Amgen Inc 's cumulative 12 months Net Income continue to fall, but on the faster rate at -19.22% year on year, at Mar 31 2022 compare to the -18.87% decrease at Dec 31 2021. If the Amgen Inc 's fiscal year would end at Mar 31 2022, annual Net Income would be $5,723 millions.

In the Healthcare sector 95 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 566 to 1442.

Net Income TTM Q/Q Growth Statistics
High Average Low
281.2 %
4.18 %
-75.8 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 96
Overall # 1442

Net Income TTM Y/Y Growth Statistics
High Average Low
324.15 %
18.6 %
-74.37 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 68
S&P 500 # 1023
Cumulative Net Income growth Comment
Amgen Inc 's cumulative 12 months Net Income continue to fall, but on the faster rate at -19.22% year on year, at Mar 31 2022 compare to the -18.87% decrease at Dec 31 2021. If the Amgen Inc 's fiscal year would end at Mar 31 2022, annual Net Income would be $5,723 millions.

In the Healthcare sector 95 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 566 to 1442.

Net Income TTM Q/Q Growth Statistics
High Average Low
281.2 %
4.18 %
-75.8 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 96
Overall # 1442

Net Income TTM Y/Y Growth Statistics
High Average Low
324.15 %
18.6 %
-74.37 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 68
S&P 500 # 1023




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
AMGN's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for AMGN's Competitors
Net Income Growth for Amgen Inc 's Suppliers
Net Income Growth for AMGN's Customers

You may also want to know
AMGN's Annual Growth Rates AMGN's Profitability Ratios AMGN's Asset Turnover Ratio AMGN's Dividend Growth
AMGN's Roe AMGN's Valuation Ratios AMGN's Financial Strength Ratios AMGN's Dividend Payout Ratio
AMGN's Roa AMGN's Inventory Turnover Ratio AMGN's Growth Rates AMGN's Dividend Comparisons



Companies with similar Net Income fall for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2022
Chemed Corporation-1.88%$ -1.882 millions
Biomx Inc -2.77%$ -2.773 millions
Ironwood Pharmaceuticals inc -2.82%$ -2.818 millions
Corcept Therapeutics Inc-2.85%$ -2.847 millions
Msa Safety Inc-2.89%$ -2.891 millions
Merit Medical Systems Inc-3.77%$ -3.769 millions
Addus Homecare Corporation-4.77%$ -4.767 millions
Idexx Laboratories Inc-5.05%$ -5.054 millions
Hca Healthcare Inc -7.28%$ -7.278 millions
National Research Corporation-7.51%$ -7.506 millions
Amgen Inc -10.33%$ -10.328 millions
Regeneron Pharmaceuticals Inc -12.71%$ -12.706 millions
Organon and Co -12.78%$ -12.782 millions
Intuitive Surgical Inc -15.12%$ -15.119 millions
Apollo Medical Holdings Inc -16.50%$ -16.496 millions
Encompass Health Corporation-17.09%$ -17.093 millions
Molecular Templates Inc -19.30%$ -19.296 millions
Royalty Pharma Plc-19.43%$ -19.434 millions
Natus Medical Inc-20.58%$ -20.576 millions
Fulgent Genetics Inc -23.49%$ -23.486 millions
Quest Diagnostics Inc-23.88%$ -23.878 millions
Hologic Inc-26.49%$ -26.488 millions
Integra Lifesciences Holdings Corp-27.52%$ -27.521 millions
Universal Health Services Inc -27.77%$ -27.765 millions
National Healthcare Corp-27.97%$ -27.966 millions
Incyte Corp-29.03%$ -29.033 millions
Davita Inc -29.44%$ -29.439 millions
Reynolds Consumer Products Inc -29.73%$ -29.730 millions
Semler Scientific inc -31.11%$ -31.105 millions
Align Technology inc -32.98%$ -32.977 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

STRI's Profile

Stock Price

STRI's Financials

Business Description

Fundamentals

Charts & Quotes

STRI's News

Suppliers

STRI's Competitors

Customers & Markets

Economic Indicators

STRI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071